Background: A knowledge gap remains in how the rate of body weight reduction impacts efficacy and safety of obesity management medications.This SURMOUNT-5 post hoc analysis aimed to define rapid responders and evaluated efficacy and safety of tirzepatide vs. semaglutide in rapid responders vs non-rapid responders.Methods: Rapid responders and non-rapid responders were defined as participants that obtained 15% and <15% body weight reduction by Week 24, respectively.Baseline characteristics, and proportion of participants achieving body weight reduction thresholds by Week 72 were assessed.End-of-study safety and gastrointestinal adverse events measures were summarized.Results: Overall, 32.3% were rapid responders (tirzepatide: 44%, semaglutide: 21%).The proportions of participants achieving body weight reduction thresholds by Week 72 were higher for rapid responders vs non-rapid responders.Safety trends for tirzepatide and semaglutide were similar between responder groups.A numerically higher number of gastrointestinal/hepatobiliary adverse events were reported in rapid responders.Study treatment completion was similar among rapid responders and non-rapid responders for both treatments. Conclusions:In this post hoc analysis of SURMOUNT-5, a greater proportion of tirzepatidetreated participants in both responder groups achieved all body weight reduction thresholds vs semaglutide.Although rapid responders experienced more gastrointestinal/hepatobiliary adverse events in both treatments, this did not affect rates of study treatment completion relative to nonrapid responders.
Aronne et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: